



Independent observer
of the Global Fund

ROUND EIGHT RESULTS, BY COUNTRY

Based on advice from the TRP, the Board divided eligible Round 8 proposals into five Categories, as follows:

- Category 1: Approved proposals requiring no or minor clarifications, which need to be provided within 8 weeks and then given a final approval by the TRP Chair and/or Vice-Chair.
- Category 2: Proposals that are approved in principle, subject to the required clarifications being provided within a limited timeframe (6 weeks for the applicant to provide an initial detailed response to the TRP queries, and a further 3 months to obtain the final TRP approval should further clarifications be requested). The TRP Chair and Vice-Chair need to give final approval.
- Category 2B: Proposals that are treated as those in Category 2, but are regarded as being relatively weak, on grounds of technical merit and/or issues of feasibility and likelihood of effective implementation.
- Category 3: Proposals not approved in their present form, though applicants are encouraged to resubmit in Round 9 following major revision.
- Category 4: Proposals that are rejected, with applicants not encouraged to resubmit in any similar form.

The Board approved “in principle” (to use its precise words) all proposals in Categories 1, 2 and 2B. However, some of the approvals are immediate and some are delayed, depending on future availability of funds. The prioritization is handled as follows:

- Category 1 proposals are approved immediately.
- Each country submitting a Category 2 or 2B proposal is assigned a disease burden index of 4 or 1

according to whether the disease burden is “very high” or not “very high”. And each such country is assigned a poverty index of 4, 2 or 0 according to whether the country is low income, lower-middle income, or upper-middle income. The sum of these two indexes creates the Composite Index, whose value is therefore between 8 and 1. The higher the country’s Composite Index, the sooner its Category 2 or 2B proposal will be approved.

- Category 2 proposals with a Composite Index of 8, 6 or 5 are immediately approved.
- Remaining Category 2 and 2B proposals will be approved in the following order, as pledges by donors to the Fund become available in the course of 2008-9:

1. Category 2, Composite Index 3
2. Category 2B, Composite Index 8
3. Category 2B, Composite Index 6
4. Category 2B, Composite Index 5
5. Category 2B, Composite Index 3

The number of Round 8 grants per Category and Composite Index are as follows:

Table 4: Round 8 results by Category and Composite Index

Category and Composite Index	Number of proposals	Amount requested (Years 1-2)
Immediate approval: Category 1	16	USD 0.45 b.
Immediate approval: Category 2, Composite Index 8, 6 or 5	43	USD 1.68 b.
Delayed approval: Category 2, Composite Index 3	8	USD 0.18 b.
Delayed approval: Category 2B, Composite Index 8	6	USD 0.44 b.
Delayed approval: Category 2B, Composite Index 6	6	USD 0.10 b.
Delayed approval: Category 2B, Composite Index 5	8	USD 0.13 b.
Delayed approval: Category 2B, Composite Index 3	7	USD 0.09 b.
Subtotal: All Approved Proposals:	94	USD 3.06 b.

Not Approved: Category 3	63	USD 1.75 b.
Not Approved: Category 4	17	USD 0.43 b.
Not Approved: Removed sub-components of approved proposalsn/a		USD 0.56 b.
Subtotal: All Non-Approved Proposals:	80	USD 2.73 b.
Total: All Proposals	174	USD 5.79 b.

Round 8 results by applicant were as in Tables 5 and 6, below.

Table 5: Round 8 Results, by Country

Country	Disease component	Applicant	Decision	Category (defined above)	Composite Index (defined above)	Amount requested (Years 1-2)	Amount requested (Years 1-5)
Afghanistan	Malaria (disease part + HSS part)	CCM	Delayed approval	2B	5	EUR 30,075,545	EUR 55,397,259
<u>Afghanistan</u>	<u>TB</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>1</u>	<u>n/a</u>	<u>EUR</u> <u>7,394,272</u>	<u>EUR</u> <u>22,669,094</u>
Algeria	HIV	CCM	Not approved	4	n/a	USD 15,252,168	USD 32,720,961
Angola	HIV	CCM	Not approved	4	n/a	USD 75,142,046	USD 235,955,998
Angola	TB	CCM	Not approved	4	n/a	USD 11,756,766	USD 25,098,444

<u>Armenia</u>	<u>HIV (HSS part)</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>6</u>	<u>EUR</u> <u>1,466,930</u>	<u>EUR</u> <u>2,062,995</u>
Armenia	HIV (disease part)	CCM	Not approved	n/a	n/a	EUR 2,394,212	EUR 6,257,962
<u>Armenia</u>	<u>TB</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>1</u>	<u>n/a</u>	<u>EUR</u> <u>2,006,371</u>	<u>EUR</u> <u>6,205,708</u>
Bangladesh	HIV	CCM	Not approved	3	n/a	USD 14,964,866	USD 48,892,309
Bangladesh	Malaria	CCM	Not approved	3	n/a	USD 22,729,707	USD 68,436,372
<u>Bangladesh</u>	<u>TB (disease part + HSS part)</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>8</u>	<u>USD</u> <u>5,627,763</u>	<u>USD</u> <u>77,430,875</u>
<u>Belarus</u>	<u>HIV (disease part + HSS part)</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>1</u>	<u>n/a</u>	<u>EUR</u> <u>11,120,812</u>	<u>EUR</u> <u>25,389,385</u>
Belarus	TB	CCM	Not approved	3	n/a	EUR 14,254,281	EUR 31,226,265
Benin	Malaria	CCM	Not approved	3	n/a	EUR 26,909,499	EUR 26,909,499
Benin	TB	CCM	Not approved	3	n/a	EUR 3,556,947	EUR 6,658,804
Bolivia	HIV	CCM	Not approved	3	n/a	USD 7,763,930	USD 23,802,395
Bolivia	Malaria	CCM	Delayed approval	2B	3	USD 6,744,407	USD 15,578,630
Bolivia	TB	CCM	Not approved	4	n/a	USD 9,191,385	USD 16,777,841
Bosnia & Herzegovina	HIV	CCM	Not approved	3	n/a	EUR 12,336,077	EUR 29,441,571

Bosnia & Herzegovina	TB	CCM	Not approved	3	n/a	EUR 5,722,028	EUR 9,796,973
Brazil	HIV	CCM	Not approved	3	n/a	EUR 9,372,000	EUR 30,000,000
Brazil	Malaria	CCM	Delayed approval	2	3	EUR 20,659,117	EUR 42,023,909
Brazil	TB	CCM	Not approved	3	n/a	EUR 40,191,174	EUR 80,560,970
Bulgaria	TB	CCM	Delayed approval	2B	3	EUR 3,661,435	EUR 10,527,766
Burkina Faso	HIV	CCM	Not approved	3	n/a	EUR 24,844,539	EUR 48,473,676
<u>Burkina Faso</u>	<u>Malaria</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>8</u>	<u>EUR</u> <u>53,120,303</u>	<u>EUR</u> <u>63,203,438</u>
Burkina Faso	TB (disease part + HSS part)	CCM	Delayed approval	2B	8	EUR 12,045,997	EUR 27,167,685
Burundi	HIV	CCM	Delayed approval	2B	8	USD 41,315,145	USD 159,105,087
Cambodia	HIV	CCM	Not approved	3	n/a	USD 38,283,888	USD 134,514,948
Cambodia	TB (disease part + HSS part)	CCM	Not approved	3	n/a	USD 11,449,113	USD 34,686,505
Cameroon	HIV	CCM	Not approved	3	n/a	EUR 28,961,003	EUR 66,797,527
Cameroon	TB	CCM	Not approved	3	n/a	EUR 7,015,400	EUR 13,782,656
Cape Verde	HIV	CCM	Delayed approval	2	3	USD 5,321,184	USD 12,578,727

<u>Central African Republic</u>	<u>Malaria</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>8</u>	<u>EUR</u> <u>10,871,833</u>	<u>EUR</u> <u>30,971,995</u>
Central African Republic	TB	CCM	Not approved	3	n/a	EUR 9,742,228	EUR 22,482,120
<u>Chad</u>	<u>HIV</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>8</u>	<u>EUR</u> <u>29,702,927</u>	<u>EUR</u> <u>63,244,477</u>
Chad	TB	CCM	Delayed approval	2B	8	EUR 3,427,453	EUR 5,385,007
<u>China</u>	<u>HIV</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>6</u>	<u>EUR</u> <u>15,747,191</u>	<u>EUR</u> <u>44,128,188</u>
China	Malaria	CCM	Not approved	3	n/a	EUR 29,681,060	EUR 61,332,628
China	TB	CCM	Delayed approval	2B	6	EUR 24,012,517	EUR 87,664,363
Colombia	HIV	CCM	Not approved	3	n/a	EUR 12,254,560	EUR 32,867,073
Colombia	Malaria	CCM	Delayed approval	2	3	EUR 16,997,092	EUR 32,262,166
Colombia	TB	CCM	Not approved	3	n/a	EUR 11,968,726	EUR 22,919,271
Comoros	HIV	CCM	Not approved	4	n/a	EUR 1,235,586	EUR 2,229,001
<u>Comoros</u>	<u>Malaria (disease part)</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>5</u>	<u>EUR</u> <u>5,280,932</u>	<u>EUR</u> <u>11,788,954</u>
Comoros	Malaria (HSS part)	CCM	Not approved	n/a	n/a	EUR 1,061,171	EUR 2,834,024
<u>Congo (Democratic Republic of)</u>	<u>HIV</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>8</u>	<u>USD</u> <u>79,225,696</u>	<u>USD</u> <u>262,911,091</u>

<u>Congo (Democratic Republic of)</u>	<u>Malaria</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>8</u>	<u>USD</u> <u>153,997,553</u>	<u>USD</u> <u>393,102,357</u>
Congo (Democratic Republic of)	TB (disease part + HSS part)	CCM	Not approved	3	n/a	USD 71,422,674	USD 199,682,709
Congo (Republic of)	Malaria	CCM	Delayed approval	2B	6	EUR 25,465,537	EUR 54,135,175
Congo (Republic of)	TB	CCM	Delayed approval	2B	6	EUR 2,303,089	EUR 5,005,041
Cote d'Ivoire	HIV (disease part + HSS part)	CCM	Not approved	3	n/a	EUR 55,758,904	EUR 142,745,182
<u>Cote d'Ivoire</u>	<u>Malaria</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>8</u>	<u>EUR</u> <u>139,365,869</u>	<u>EUR</u> <u>180,298,316</u>
Cote d'Ivoire	TB	CCM	Not approved	3	n/a	EUR 7,152,767	EUR 17,886,903
Djibouti	Malaria	CCM	Not approved	3	n/a	EUR 4,335,600	EUR 10,391,353
Djibouti	TB	CCM	Not approved	4	n/a	EUR 3,912,029	EUR 8,688,954
Dominican Republic	Malaria	CCM	Delayed approval	2	3	USD 4,492,517	USD 8,703,257
Ecuador	HIV	CCM	Not approved	3	n/a	USD 14,389,246	USD 35,615,171
Ecuador	Malaria	CCM	Delayed approval	2	3	USD 8,374,965	USD 15,108,812
Ecuador	TB	CCM	Not approved	3	n/a	USD 14,066,522	USD 32,819,024
<u>Eritrea</u>	<u>HIV (disease part)</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>8</u>	<u>USD</u> <u>17,071,740</u>	<u>USD</u> <u>45,135,676</u>

Eritrea	HIV (HSSpart)CCM		Not approved	n/a	n/a	USD 6,087,808	USD 14,939,526
Ethiopia	<u>Malaria</u> (disease part + HSS part) CCM		<u>Immediate approval</u>	<u>1</u>	<u>n/a</u>	<u>USD</u> <u>148,412,502</u>	<u>USD</u> <u>291,064,713</u>
Fiji	TB (disease part + HSS part) CCM		Delayed approval	2B	3	USD 4,789,119	USD 9,929,474
Gabon	<u>HIV</u> CCM		<u>Immediate approval</u>	<u>1</u>	<u>n/a</u>	<u>EUR</u> <u>6,879,029</u>	<u>EUR</u> <u>17,006,207</u>
Gabon	Malaria CCM		Not approved	3	n/a	EUR 5,030,319	EUR 13,851,883
Gambia	<u>HIV (disease part + HSS part)</u> CCM		<u>Immediate approval</u>	<u>2</u>	<u>5</u>	<u>EUR</u> <u>15,250,763</u>	<u>EUR</u> <u>36,582,801</u>
Ghana	<u>HIV</u> CCM		<u>Immediate approval</u>	<u>2</u>	<u>8</u>	<u>USD</u> <u>51,498,200</u>	<u>USD</u> <u>99,858,800</u>
Ghana	<u>Malaria (disease part)</u> CCM		<u>Immediate approval</u>	<u>2</u>	<u>8</u>	<u>USD</u> <u>39,639,118</u>	<u>USD</u> <u>158,030,372</u>
Ghana	Malaria (HSS part) CCM		Not approved	n/a	n/a	USD 4,462,500	USD 13,420,570
Guatemala	HIV (disease part + HSS part) CCM		Not approved	4	n/a	EUR 37,104,756	EUR 115,595,987
Guatemala	Malaria CCM		Not approved	3	n/a	EUR 21,586,329	EUR 41,174,990
Guinea-Bissau	<u>TB (HSS part) CCM</u>		<u>Immediate approval</u>	<u>2</u>	<u>5</u>	<u>EUR</u> 595,684 <u>1,286,514</u>	<u>EUR</u> <u>1,286,514</u>
Guinea-Bissau	TB (disease part) CCM		Not approved	n/a	n/a	EUR 7,818,909	EUR 21,213,426
Guyana	<u>HIV (HSS part)</u> CCM		<u>Immediate approval</u>	<u>2</u>	<u>6</u>	<u>USD</u> <u>4,637,491</u>	<u>USD</u> <u>10,094,303</u>

Guyana	HIV (disease part)	CCM	Not approved	n/a	n/a	USD 6,005,402	USD 18,370,517
Guyana	Malaria	CCM	Not approved	3	n/a	USD 2,993,178	USD 5,573,355
Guyana	TB	CCM	Delayed approval	2B	3	USD 3,087,615	USD 7,125,899
Haiti	Malaria	CCM	Delayed approval	2B	5	USD 33,402,457	USD 50,046,179
Haiti	TB (disease part + HSS part)	CCM	Not approved	3	n/a	USD 31,167,222	USD 59,742,348
Honduras	HIV	CCM	Not approved	3	n/a	USD 5,334,334	USD 13,389,159
Honduras	TB (disease part + HSS part)	CCM	Not approved	3	n/a	USD 8,031,166	USD 16,170,525
India	HIV	CCM	Not approved	3	n/a	EUR 21,263,481	EUR 75,212,496
India	Malaria	CCM	Not approved	3	n/a	EUR 39,883,180	EUR 100,310,326
India	TB	CCM	Not approved	3	n/a	EUR 32,420,155	EUR 79,915,954
<u>Indonesia</u>	<u>HIV</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>1</u>	<u>n/a</u>	<u>USD</u> <u>45,384,545</u>	<u>USD</u> <u>130,653,560</u>
Indonesia	Malaria	CCM	Delayed approval	2	3	USD 73,453,889	USD 120,092,536
<u>Indonesia</u>	<u>TB</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>1</u>	<u>n/a</u>	<u>USD</u> <u>28,106,251</u>	<u>USD</u> <u>93,001,059</u>
Iran	HIV	CCM	Delayed approval	2B	6	USD 10,328,021	USD 32,354,404

Kazakhstan	HIV	CCM	Not approved	3	n/a	USD 13,880,664	USD 35,851,200
Kazakhstan	Malaria	CCM	Not approved	4	n/a	USD 897,612	USD 1,376,877
Kazakhstan	TB	CCM	Delayed approval	2B	3	USD 37,557,518	USD 69,880,919
Kenya	HIV	CCM	Not approved	4	n/a	USD 105,743,946	USD 129,929,146
Kenya	Malaria	CCM	Not approved	3	n/a	USD 89,634,705	USD 200,581,638
Kenya	TB (disease part + HSS part)	CCM	Not approved	3	n/a	USD 41,216,118	USD 137,406,953
Korea (Democratic People's Republic of)	HIV	CCM	Not approved	3	n/a	EUR 15,119,159	EUR 28,699,056
<u>Korea (Democratic People's Republic of)</u>	<u>Malaria</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>5</u>	<u>EUR 9,542,511</u>	<u>EUR 18,348,551</u>
Korea (Democratic People's Republic of)	TB	CCM	Delayed approval	2B	5	EUR 17,686,423	EUR 47,102,407
Kyrgyz Republic	HIV	Sub-CCM	Not approved	4	n/a	USD 3,560,042	USD 6,770,643
<u>Kyrgyz Republic</u>	<u>Malaria</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>5</u>	<u>USD 4,530,888</u>	<u>USD 8,788,180</u>
Kyrgyz Republic	TB	CCM	Not approved	3	n/a	USD 7,507,988	USD 24,622,765
<u>Lao People's Democratic Republic</u>	<u>HIV (disease part + HSS part)</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>8</u>	<u>USD 9,114,326</u>	<u>USD 24,569,609</u>
<u>Lesotho</u>	<u>HIV (disease part + HSS part)</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>6</u>	<u>USD 39,773,696</u>	<u>USD 103,429,628</u>

Lesotho	TB	CCM	Delayed approval	2B	6	USD 10,967,381	USD 28,083,618
<u>Liberia</u>	<u>HIV (disease part + HSS part)</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>8</u>	<u>USD</u> <u>20,199,587</u>	<u>USD</u> <u>78,235,151</u>
<u>Madagascar</u>	<u>HIV</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>5</u>	<u>USD</u> <u>11,768,300</u>	<u>USD</u> <u>36,037,600</u>
Madagascar	TB	CCM	Delayed approval	2B	5	USD 8,987,239	USD 22,797,620
<u>Mali</u>	<u>HIV (disease part)</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>8</u>	<u>EUR</u> <u>40,526,846</u>	<u>EUR</u> <u>126,634,447</u>
Mali	HIV (HSS part)	CCM	Not approved	n/a	n/a	EUR 21,852,585	EUR 49,979,708
<u>Mauritania</u>	<u>HIV (HSS part)</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>1</u>	<u>n/a</u>	<u>USD</u> <u>2,772,376</u>	<u>USD</u> <u>3,942,505</u>
Mauritania	HIV (disease part)	CCM	Not approved	n/a	n/a	USD 9,367,617	USD 22,266,256
<u>Mauritius</u>	<u>HIV</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>1</u>	<u>n/a</u>	<u>EUR</u> <u>4,052,662</u>	<u>EUR</u> <u>7,890,632</u>
Moldova	HIV	CCM	Delayed approval	2B	6	EUR 8,606,392	EUR 16,723,816
<u>Moldova</u>	<u>TB</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>1</u>	<u>n/a</u>	<u>EUR</u> <u>5,281,042</u>	<u>EUR</u> <u>13,322,904</u>
<u>Mozambique</u>	<u>HIV (HSS part)</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>8</u>	<u>USD</u> <u>13,177,452</u>	<u>USD</u> <u>34,874,346</u>
Mozambique	HIV (disease part)	CCM	Not approved	n/a	n/a	USD 39,073,131	USD 170,770,762
Mozambique	Malaria	CCM	Not approved	3	n/a	USD 78,152,630	USD 210,466,897

Namibia	HIV	CCM	Not approved	3	n/a	USD 64,688,284	USD 160,505,034
Nepal	HIV (disease part + HSS part)	CCM	Not approved	3	n/a	USD 35,249,649	USD 90,220,063
Nicaragua	HIV	CCM	Delayed approval	2	3	USD 31,385,337	USD 65,390,510
<u>Nigeria</u>	<u>HIV (HSS part)</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>8</u>	<u>USD</u> <u>75,055,363</u>	<u>USD</u> <u>178,030,052</u>
Nigeria	HIV (disease part)	CCM	Not approved	n/a	n/a	USD 293,867,577	USD 831,612,641
Nigeria	Malaria	CCM	Delayed approval	2B	8	USD 334,351,033	USD 599,810,494
Nigeria	TB	CCM	Not approved	3	n/a	USD 42,169,586	USD 181,584,855
Pakistan	HIV	CCM	Not approved	3	n/a	USD 18,636,708	USD 66,219,051
<u>Pakistan</u>	<u>TB</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>8</u>	<u>USD</u> <u>9,810,559</u>	<u>USD</u> <u>26,682,133</u>
Panama	HIV	CCM	Not approved	3	n/a	USD 4,949,840	USD 13,592,440
<u>Papua New Guinea</u>	<u>Malaria</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>5</u>	<u>USD</u> <u>70,139,822</u>	<u>USD</u> <u>152,252,244</u>
<u>Paraguay</u>	<u>HIV (disease part)</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>6</u>	<u>EUR</u> <u>4,765,763</u>	<u>EUR</u> <u>13,314,074</u>
Paraguay	HIV (HSS part)	CCM	Not approved	n/a	n/a	EUR 1,514,597	EUR 3,267,216
Paraguay	Malaria	CCM	Not approved	3	n/a	EUR 4,403,483	EUR 8,558,518

Paraguay	TB	CCM	Not approved	3	n/a	EUR 8,277,793	EUR 18,576,825
Peru	HIV (disease part + HSS part)	CCM	Not approved	3	n/a	EUR 30,545,347	EUR 50,546,403
<u>Peru</u>	<u>TB</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>1</u>	<u>n/a</u>	<u>EUR 11,484,622</u>	<u>EUR 22,229,143</u>
Philippines	HIV (disease part + HSS part)	CCM	Not approved	3	n/a	EUR 25,581,667	EUR 42,391,843
Russian Federation	TB	CCM	Not approved	3	n/a	EUR 65,687,022	EUR 139,199,580
Russian Federation	TB (disease part + HSS part)	Sub-CCM	Not approved	4	n/a	EUR 18,808,972	EUR 33,180,557
Rwanda	HIV	CCM	Not approved	3	n/a	USD 15,591,988	USD 38,979,970
<u>Rwanda</u>	<u>Malaria (disease part)</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>5</u>	<u>USD 58,567,001</u>	<u>USD 138,469,243</u>
Rwanda	Malaria (HSS part)	CCM	Not approved	n/a	n/a	USD 33,702,875	USD 48,541,601
Sao Tome and Principe	HIV	CCM	Not approved	3	n/a	USD 568,464	USD 1,529,157
<u>Sao Tome and Principe</u>	<u>TB</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>1</u>	<u>n/a</u>	<u>USD 1,132,914</u>	<u>USD 2,608,818</u>
Senegal	HIV (disease part + HSS part)	CCM	Not approved	3	n/a	EUR 54,507,488	EUR 136,440,454
Senegal	TB	CCM	Not approved	3	n/a	EUR 6,930,243	EUR 17,791,333
Serbia	HIV	CCM	Delayed approval	2	3	EUR 3,766,988	EUR 12,406,231

Solomon Islands	HIV (disease part)	CCM	Not approved	n/a	n/a	USD 4,570,062	USD 10,472,323
Solomon Islands	HIV (HSS part)	CCM	Delayed approval	2B	5	USD 845,725	USD 1,686,884
Solomon Islands	TB	CCM	Delayed approval	2B	5	USD 3,608,714	USD 7,334,716
<u>Somalia</u>	<u>HIV (disease part + HSS part)</u>	<u>Non-CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>5</u>	<u>USD 25,669,049</u>	<u>USD 60,261,684</u>
South Africa	HIV	CCM	Not approved	3	n/a	USD 91,680,358	USD 259,056,796
South Africa	TB	CCM	Not approved	4	n/a	USD 68,229,369	USD 194,670,986
Sri Lanka	Malaria	CCM	Delayed approval	2B	3	USD 24,040,444	USD 40,915,151
Sudan (Northern Sector)	TB (disease part + HSS part)	CCM	Delayed approval	2B	8	USD 17,979,663	USD 58,048,795
Sudan (Southern Sector)	HIV (disease part + HSS part)	Sub-CCM	Not approved	3	n/a	USD 28,482,979	USD 124,015,542
<u>Swaziland</u>	<u>HIV (HSS part)</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>6</u>	<u>USD 8,180,726</u>	<u>USD 15,136,442</u>
Swaziland	HIV (disease part)	CCM	Not approved	n/a	n/a	USD 49,055,285	USD 90,214,010
<u>Swaziland</u>	<u>Malaria</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>1</u>	<u>n/a</u>	<u>USD 5,637,713</u>	<u>USD 13,880,938</u>
<u>Swaziland</u>	<u>TB</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>6</u>	<u>USD 4,785,540</u>	<u>USD 11,839,346</u>
<u>Tajikistan</u>	<u>HIV</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>8</u>	<u>EUR 13,264,761</u>	<u>EUR 34,578,129</u>

<u>Tajikistan</u>	<u>Malaria</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>5</u>	<u>EUR</u> <u>5,224,796</u>	<u>EUR</u> <u>9,615,246</u>
<u>Tajikistan</u>	<u>TB (disease part + HSS part)</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>5</u>	<u>EUR</u> <u>9,840,404</u>	<u>EUR</u> <u>17,534,572</u>
<u>Tanzania (United Republic of)</u>	<u>HIV (disease part)</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>8</u>	<u>USD</u> <u>145,848,085</u>	<u>USD</u> <u>598,106,619</u>
<u>Tanzania (United Republic of)</u>	<u>HIV (HSS part)</u>	<u>CCM</u>	<u>Not approved</u>	<u>n/a</u>	<u>n/a</u>	<u>USD</u> <u>65,422,207</u>	<u>USD</u> <u>96,794,019</u>
<u>Tanzania (United Republic of)</u>	<u>Malaria</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>5</u>	<u>USD</u> <u>111,586,404</u>	<u>USD</u> <u>113,335,025</u>
<u>Thailand</u>	<u>HIV</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>6</u>	<u>USD</u> <u>38,254,259</u>	<u>USD</u> <u>106,123,200</u>
<u>Thailand</u>	<u>TB</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>1</u>	<u>n/a</u>	<u>USD</u> <u>12,420,804</u>	<u>USD</u> <u>30,547,583</u>
<u>Togo</u>	<u>HIV</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>8</u>	<u>EUR</u> <u>31,775,839</u>	<u>EUR</u> <u>81,340,190</u>
<u>Tunisia</u>	<u>TB</u>	<u>CCM</u>	<u>Delayed approval</u>	<u>2B</u>	<u>3</u>	<u>USD</u> <u>4,400,014</u>	<u>USD</u> <u>7,560,548</u>
<u>Turkmenistan</u>	<u>TB</u>	<u>CCM</u>	<u>Not approved</u>	<u>3</u>	<u>n/a</u>	<u>USD</u> <u>10,649,147</u>	<u>USD</u> <u>20,279,651</u>
<u>Ukraine</u>	<u>TB</u>	<u>CCM</u>	<u>Not approved</u>	<u>3</u>	<u>n/a</u>	<u>USD</u> <u>36,251,905</u>	<u>USD</u> <u>94,715,697</u>
<u>Uruguay</u>	<u>HIV</u>	<u>CCM</u>	<u>Not approved</u>	<u>3</u>	<u>n/a</u>	<u>USD</u> <u>8,951,242</u>	<u>USD</u> <u>21,393,157</u>
<u>Uzbekistan</u>	<u>HIV</u>	<u>CCM</u>	<u>Not approved</u>	<u>3</u>	<u>n/a</u>	<u>USD</u> <u>26,428,887</u>	<u>USD</u> <u>79,669,868</u>
<u>Uzbekistan</u>	<u>Malaria</u>	<u>CCM</u>	<u>Delayed approval</u>	<u>2B</u>	<u>5</u>	<u>USD</u> <u>2,789,923</u>	<u>USD</u> <u>6,144,821</u>

Uzbekistan	TB	CCM	Delayed approval	2B	5	USD 13,881,631	USD 56,124,183
<u>Vietnam</u>	<u>HIV</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>8</u>	<u>USD</u> <u>14,577,204</u>	<u>USD</u> <u>48,693,061</u>
<u>West Bank and Gaza</u>	<u>TB</u>	<u>Non-CCM</u>	<u>Immediate approval</u>	<u>1</u>	<u>n/a</u>	<u>EUR</u> 972,386	<u>EUR</u> <u>2,152,074</u>
Yemen	HIV	CCM	Not approved	3	n/a	USD 6,495,225	USD 25,735,775
Yemen	TB	CCM	Not approved	4	n/a	USD 6,767,022	USD 19,880,527
<u>Zambia</u>	<u>HIV (disease part + HSS part)</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>1</u>	<u>n/a</u>	<u>USD</u> <u>144,079,863</u>	<u>USD</u> <u>307,273,164</u>
Zanzibar	HIV	CCM	Not approved	4	n/a	EUR 4,127,078	EUR 7,274,018
<u>Zanzibar</u>	<u>Malaria (disease part + HSS part)</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>5</u>	<u>EUR</u> <u>5,648,340</u>	<u>EUR</u> <u>12,355,905</u>
<u>Zimbabwe</u>	<u>HIV</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>8</u>	<u>USD</u> <u>86,821,730</u>	<u>USD</u> <u>296,752,070</u>
<u>Zimbabwe</u>	<u>Malaria (disease part + HSS part)</u>	<u>CCM</u>	<u>Immediate approval</u>	<u>2</u>	<u>5</u>	<u>USD</u> <u>70,994,472</u>	<u>USD</u> <u>141,316,927</u>
Zimbabwe	TB	CCM	Delayed approval	2B	8	USD 29,538,652	USD 58,298,297

Table 6: Round 8 results for regional applicants

Country	Disease	Applicant	Decision	Category (defined above)	Composite Index (defined above)	Requested (Years 1-2)	Requested (Years 1-5)
---------	---------	-----------	----------	--------------------------	---------------------------------	-----------------------	-----------------------

CARE (India, Nepal, Bangladesh)	HIV	Regional organization	Not approved ⁴	n/a	EUR 14,145,331	EUR 40,817,080
CCLAB (Guatemala, El Salvador, Honduras, Nicaragua, Dom. Rep., Panama, Costa Rica, Belize)	HIV	Regional Coordinating Mechanism	Not approved ⁴	n/a	USD 20,292,270	USD 46,811,258
COPRECOS LAC (Colombia, El Salvador, Nicaragua, Panama, Paraguay, Dom. Rep., Uruguay, Argentina, Belize, Brazil, Ecuador, Guatemala, Haiti, Honduras, Peru, Chile, Costa Rica, Venezuela)	HIV	Regional organization	Not approved ³	n/a	USD 23,122,297	USD 68,666,796
GLIA (Burundi, DRC, Kenya, Rwanda, Tanzania, Uganda)	HIV	Regional organization	Not approved ⁴	n/a	USD 10,824,037	USD 27,044,765
SADC (Angola, Botswana, Namibia, Zambia, Zimbabwe)	Malaria (disease part + HSS part)	Regional Coordinating Mechanism	Not approved ³	n/a	USD 36,018,686	USD 86,985,372

[Read More](#)
